Circular RNA 0001313 Knockdown Suppresses Non-Small Cell Lung Cancer Cell Proliferation and Invasion via the microRNA-452/HMGB3/ERK/MAPK Axis

This article was published in the following Dove Press journal:
International Journal of General Medicine

Shihao Zhang*
Jiansheng Liu*
Taiwen Yuan
Huiyu Liu
Chengwei Wan
Yonghong Le

Department of Respiratory and Critical Care Medicine, Ganzhou People's Hospital, Ganzhou 341000, Jiangxi, People's Republic of China

*These authors contributed equally to this work

Background: Non-small cell lung cancer (NSCLC) seriously endangers human health. Circular RNAs (circRNAs) regulate diverse types of cancers, including NSCLC. This study investigated the possible mechanism of *circ0001313* in NSCLC.

Materials and Methods: *Circ0001313* expression in NSCLC tissues was measured, and its correlation with clinicopathological features was analyzed. The binding relationships among *circ0001313*, microRNA (miR)-452 and *HMGB3* were tested. The gain and loss of functions were performed to examine NSCLC cell malignant behaviors. After *HMGB3* overexpression, ERK/MAPK pathway-related protein levels were detected. Subsequently, the rescue experiment was further performed using an ERK/MAPK pathway inhibitor PD98059.

Results: Abnormally elevated *circ0001313* and decreased *miR-452* in NSCLC cells were observed. *Circ0001313* silencing or *miR-452* overexpression significantly reduced NSCLC cell proliferation and invasion. *Circ0001313* competitively bound to *miR-452* to upregulate *HMGB3*, thus promoting NSCLC cell growth. *HMGB3* overexpression activated the ERK/MAPK pathway to contribute to NSCLC development.

Conclusion: We highlighted that silencing of *circ0001313* blunted the ERK/MAPK pathway via the *miR-452/HMGB3* axis, thereby inhibiting NSCLC cell proliferation and invasion.

Keywords: non-small cell lung cancer, circular RNA 0001313, microRNA-452, *HMGB3*, ERK/MAPK pathway, proliferation and invasion

Introduction

Non-small cell lung cancer (NSCLC), accounting for about 85% cases of lung cancer, is featured by late diagnosis, rapid metastasis and high incidence of recurrence, and contributes largely to cancer-related deaths.^{1,2} NSCLC can be more accurately subdivided into lung adenocarcinoma and lung squamous cell carcinoma.³ NSCLC, as a major consequence of smoking, can lead to cancer anorexic-cachexia, resulting in weight loss, reduced food intake and decreased life quality of patients.⁴ However, due to its resistance to chemotherapeutic drugs and rapid metastasis characteristics, NSCLC treatment options are limited and the overall survival rates for NSCLC patients remain low.⁵ Therefore, it is urgent to search for new therapies to improve outcomes in NSCLC.

Correspondence: Yonghong Le
Department of Respiratory and Critical Care Medicine, Ganzhou People's Hospital, No. 17, Hongqi Avenue, Zhanggong District, Ganzhou 341000, Jiangxi, People's Republic of China
Tel/Fax +8613879769189
Email Yonghongle3112@163.com

Circular RNAs (circRNAs), endogenous RNAs with stable structure, have been defined as naturally occurring RNAs with high expression in the eukaryotic transcriptome.^{6,7} Emerging evidence indicates that circRNAs take part in various cancers, promising to be both diagnostic and therapeutic targets.⁸ The role of circRNAs in NSCLC progression has also been increasingly appreciated.⁹ *Circ0001313*, also known as circCCDC66, is a novel circRNA that has been evidenced to promote cancer development in colon cancer.¹⁰ In addition, *circ0001313* suppression curtailed cell proliferation by about 65% in A549 cells and by about 40% in H1299 cells, making it a potential biomarker for NSCLC.¹¹ Nevertheless, the underlying mechanism remains largely unknown.

A previous study has suggested that the occurrence and progression of NSCLC is in a close relationship with circRNA-microRNA (miR)-mRNA network.¹² miRs, defined as small noncoding RNAs, play a significant part in regulating genic expression and consequently various cellular processes, including cancer development.¹³ miRs are implicated in the clinical status of NSCLC patients and are advantageous therapeutic agents for NSCLC.¹⁴ *miR-452* expression was found to be significantly downregulated in colorectal cancer tissues relative to the adjacent noncancerous tissues, and a low level of *miR-452* was associated with larger tumor size, deeper invasion depth, and advanced tumor-node-metastasis (TNM) stage.¹⁵ More specifically, *miR-452* downregulation was significantly associated with tumor differentiation grade and tumor size in NSCLC.¹⁶ Interestingly, another circRNA, circKIAA0907 bound to *miR-452*-5p as a specific sponge for it to participate in the progression of gastric cancer.¹⁷

Hence, we speculated that *circ0001313* regulates cell behaviors in NSCLC via interacting with *miR-452* to form a circRNA-miR-mRNA network. Consequently, we performed a series of histological and molecular experiments to identify the circRNA-miR-mRNA network and to study the underlying molecular machinery, with the purpose to provide some novel therapies against NSCLC progression.

Materials and Methods

Ethics Statement

This study was supervised and approved by the ethics committee of Ganzhou People's Hospital. All participants signed the informed consent. This study conforms to all relevant ethical norms of research involving human participants.

Sample Collection

NSCLC tissues and adjacent normal tissues from 59 patients undergoing NSCLC resection were collected. All the patient samples were obtained from Ganzhou People's Hospital. The pathological diagnosis results were obtained according to the histology or biopsy of tumor samples and examined by experienced pathologists. All tissues were stored in liquid nitrogen.

Cell Culture and Transfection

Human lung epithelial BEAS-2B cells without mycoplasma contamination and NSCLC cell lines H1299, A549, NCI-H23 and NCI-H522 were selected. All the above cells were obtained from ATCC (Manassas, Virginia, USA) and cultured in 90% RPMI-1640 medium with 10% fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific Inc., Waltham, MA, USA), as well as 100 mg/mL streptomycin and 100 U/mL penicillin in a humidity-saturated incubator with 5% CO₂ at 37°C.

Vectors for transfection were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, Guangdong, China). Small interfering RNA (si-RNA) was designed and synthesized by Thermo Fisher (si-circ0001313-#1, F: 5'-CGGCUUACCCUGAGCGGAATT-3'; R: 5'-UUCCGCUCAGGGUAAGCCGTT-3'; si-circ0001313-#2, R: 5'-UUCUCCAGCAGCUCCGCCATT-3'; F: 5'-CGGAGCUGCUGGAGAAGUATT-3'). A549 cells were plated in 6-well plates (1 × 10⁶ cells/well) overnight. The transfection was performed using Lipofectamine 2000 reagent (Invitrogen Inc., Carlsbad, CA, USA). According to different experimental requirements, the transfected cells were collected for subsequent experiments.

Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted using TRIzol (Sigma-Aldrich, St Louis, MO, USA) after 48-h transfection. RNA enzyme-free ultrapure water was used to dilute 5 µL RNA sample for 20 times. An ultraviolet spectrophotometer was used to measure the optical density (OD) value at 260 nm and 280 nm. RNA concentration and purity were determined with the purity detected by the OD260/OD280 ratio. Reverse transcription was performed on the PCR amplification instrument to synthesize the cDNA template according to the instructions of the kit (Beyotime Biotechnology Co., Ltd., Shanghai, China). The required qPCR primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). The primer information is listed

Table 1 Primer Sequence for RT-qPCR

Primer	Sequence (5'-3')
<i>Circ0001313</i>	F: CTGGAGCACCTTTTCAGTGC R: TGCTCCTCCTCTGATCTGTCA
<i>miR-452</i>	F: GCGAACTGTTTGACAGAGG R: CAGTGGGTGTGGTGGAGT
<i>HMGB3</i>	F: ACAGTGAAAAGCAGCCTTACATC R: CGGGCAACTTTAGCAGGAC
U6	F: CGCAAGGATGACACG R: GAGCAGGCTGGAGAA
GAPDH	F: ATTGTTGCCATCAATGACCC R: AGTAGAGGCAGGGATGATGT

Abbreviations: RT-qPCR, reverse transcription quantitative polymerase chain reaction; miR, microRNA; HMGB3, high mobility group box 3; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

in Table 1. The total qPCR reaction volume was 10 μ L, including 5 μ L 2 $\times$ SYBR Premix (Takara Biotechnology Co., Ltd., Dalian, China), 1 μ L cDNA template, 0.5 μ L forward and reverse primers, and 3 μ L double distilled H₂O. The conditions for reaction included 30 s at 95°C (pre-denaturation), and then 40 cycles of 30 s at 95°C (denaturation), 20 s and 30 s at 72°C (annealing/extension). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was the internal reference for *circ0001313* and high mobility group box 3 (*HMGB3*), and U6 was the internal reference for *miR-452*.

Western Blot (WB)

After 48 h of transfection, cell culture medium was removed. Cells were washed three times with precooled phosphate-buffered saline (PBS) and added with radioimmunoprecipitation assay lysis buffer (MedChemExpress Co., Ltd., Monmouth Junction, NJ, USA) containing 10% protease inhibitor. Cell sample was transferred to a 1.5 mL centrifuge tube and centrifuged at 13,000 g for 10 min, and the supernatant was obtained. The protein concentration was assessed using bicinchoninic acid method. Protein was stored at -20°C. Following sodium dodecyl sulfate-polyacrylamide gel electrophoresis for protein separation, proteins were transferred to nitrocellulose membranes using wet transfer method and blocked for 1 h with 5% skim milk. After that, diluted primary rabbit polyclonal antibodies against *HMGB3* (27,465-1-AP, Proteintech Group, Inc., Wuhan, Hubei, China), extracellular signal-regulated kinase 1/2 (ERK1/2, ab17942, Abcam Inc., Cambridge, MA, USA), p-ERK1/2

(ab223500, Abcam), p38 mitogen-activated protein kinases (MAPK, 66,234-1-Ig, Proteintech), p-p38 MAPK (ab4822, Abcam) and GAPDH (60,004-1-Ig, Proteintech) were added for incubation at 4°C overnight, followed by 2-h incubation with secondary antibody immunoglobulin G (IgG, ab150077, Abcam) in a shaking table. The membranes were developed using a Bio-Rad gel imaging system (MG8600, Beijing Thmorgan Biotech Ltd., Beijing, China). Quantitation analysis was done using Image-Pro Plus 7.0 software (Media Cybernetics, Singapore).

Cell Counting Kit-8 (CCK-8) Assay

CCK-8 (Bimake, Houston, TX, USA) was conducted for cell proliferation ability detection. Cells were collected after 24 h of transfection and seeded into 96-well plates (3000 cells/well). The OD value was measured at 450 nm with a microplate plate reader.

Transwell Assay

The invasiveness of cells was detected using transwell culture system. The membrane of the apical chamber was coated with Matrigel (BD Biosciences Discovery Labware, Woburn, MA, USA). The chambers were rehydrated with serum-free media for 2 h in a 37°C incubator. The apical chamber was then hydrated with 200 μ L cell suspension containing 1×10^5 cells, and 500 μ L medium containing 10% FBS was added as chemoattractant to the basolateral chamber. After 24-h incubation at 37°C, the cells invaded were fixed with formaldehyde for 5 min, stained with 10% crystal violet for 10 min and counted under the microscope.

RNA Fluorescence in situ Hybridization (FISH)

Circ0001313 expression in A549 cells was detected by FISH Kits (C10910, RiboBio). Cell slides were placed on the bottom of the 24-well plates. A549 cells growing in logarithmic phase were detached and added to the slides (6×10^4 cells/well). When cells grew to 60–70% confluence, cells were fixed with 4% paraformaldehyde for 10 min, treated with 1 mL precooled permeating solution at 4°C for 5 min, with 200 μ L prehybridizing solution for blocking at 37°C for 30 min. At the same time, the hybridizing solution was preheated at 37°C. Under dark conditions, 2.5 μ L FISH Probe Mix storage solution (20 μ M) was added to the hybridizing solution. Afterwards, prehybridizing solution in each well was discarded, and a proper amount of hybridizing solution containing *circ0001313* probe was added for

incubation in the dark at 37°C overnight. Next, cells in each well were washed using washing solution I 3 times in the dark at 42°C (5 min each) to reduce the background signal, followed by one wash using washing solution II at 42°C, one wash using washing solution III at 42°C and one wash using 1 × PBS for 5 min. After that, cells were stained for 10 min with 4',6-diamidino-2-phenylindole staining solution. Finally, cell slides were taken out from wells and fixed with the sealing agent for fluorescence detection. All the above operations were performed under the condition of avoiding light. The specific probe of *circ0001313* was synthesized by RiboBio (Dig-5'-CTGGAGCACCCCTTTCAAAGGTGTC AGTATG-3'-Dig).

Dual-Luciferase Reporter Gene Assay

The binding sites between *circ0001313* and *miR-452* were obtained using the bioinformatics prediction website StarBase (<http://starbase.sysu.edu.cn/index.php>). The fragment sequences containing the binding sites were obtained. Full *circ0001313* and *HMGB3* 3'UTR were cloned and amplified, respectively, into pmirGLO luciferase vectors (E1330, Promega Corporation, Madison, WI, USA), named *Circ0001313*-wild type (WT) and *HMGB3*-WT. The *circ0001313*-mutant (MUT) and *HMGB3*-MUT vectors were constructed, respectively, on the basis of the predicted binding sites. The renilla luciferase-expressing plasmids pRL-TK (E2241, Promega) was used as an internal reference. *miR-452* mimic and mimic negative control (NC) were co-transfected with luciferase report vectors into 293T cells, respectively. The fluorescence intensity was detected using a fluorescence detector (Glomax20/20, Promega).

RNA Pull-Down

Cells were transfected with 50 nM biotin-labeled WT-bio-miR-452 and MUT-bio-miR-452, followed by a 10-min incubation in a specific lysis buffer (Ambion, Austin, TX, USA). The lysate was incubated with M-280 streptavidin beads (S3762, Sigma-Aldrich) precoated with RNase-free BSA and Yeast tRNA (TRNABAK-RO, Sigma-Aldrich). The beads were incubated at 4°C for 3 h, washed twice with precooled lysis buffer, 3 times with low-salt buffer and once with high-salt buffer. The binding RNA was purified using TRIzol and then detected.

RNA Immunoprecipitation (RIP)

Cells were lysed using lysis buffer containing 25 mM Tris-HCl (pH = 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 2 mM ethylene diamine tetraacetic acid, 1 mM NaF and 0.5 mM

dithiothreitol plus a mixture of RNasin (Takara) and protease inhibitor (B14001a, Roche Diagnostics, Indianapolis, Indiana, USA). The lysate was subjected to a 30 min-centrifugation at 12,000 g. The supernatant was then incubated with anti-Ago-2 magnetic beads (BMFA-1, Biomarker Technologies Corporation, Beijing, China), with the addition of anti-IgG magnetic beads as the control. After being incubated for 4 h at 4°C, the beads were rinsed 3 times with washing buffer containing 50 mM Tris-HCl, 300 mM NaCl (pH = 7.4), 1 mM MgCl₂ and 0.1% NP-40. RNA was extracted from magnetic beads using TRIzol and then detected.

Statistical Analysis

All statistical analysis was conducted using SPSS 18.0 software (IBM Corp., Armonk, NY, USA). The comparison between two groups was analyzed using both upaired and paired *t*-test. One-way or two-way analysis of variance (ANOVA) was used for analysis of the single-factor and multi-factor comparisons among multiple groups, respectively. All data were expressed as the mean ± standard deviation of at least three independent experiments. For skew distribution data, nonparametric test was used to determine statistical significance. *p* < 0.05 indicated that the difference was statistically significant.

Results

Circ0001313 is Upregulated in NSCLC and Circ0001313 Downregulation Inhibits NSCLC Cell Proliferation and Invasion

To explore *circ0001313* expression in NSCLC, we first collected 59 cases of NSCLC tissues and adjacent normal tissues. The relationship between *circ0001313* expression and clinicopathological factors is shown in Table 2. There was no significant correlation between *circ0001313* expression and gender, age and lymph node metastasis of NSCLC patients (all *p* > 0.05), while *circ0001313* expression was correlated with tumor diameter, tissue differentiation degree and TNM stage (all *p* < 0.05). qRT-PCR found that *circ0001313* expression in NSCLC tissues was obviously upregulated (Figure 1A). *Circ0001313* expression in human lung epithelial BEAS-2B cells without mycoplasma contamination and NSCLC cell lines H1299, A549, NCI-H23 and NCI-H522 was detected using qRT-PCR. *Circ0001313* expression was increased in different degrees in NSCLC cell lines relative to that in BEAS-2B cells (Figure 1B). A549 cells with the highest *circ0001313* expression were selected for subsequent experiments.

Table 2 Relationship Between *Circ0001313* Expression and Clinicopathological Characteristics

Clinicopathological Factors	n	<i>Circ0001313</i>	
		Mean $\pm$ Standard Deviation	p
Gender			
male	40	1.64 $\pm$ 0.09	>0.05
female	19	1.72 $\pm$ 0.09	
Age (years)			
≤ 45	35	1.64 $\pm$ 0.09	>0.05
> 45	24	1.62 $\pm$ 0.09	
Tumor diameter (cm)			
≤ 4	27	1.26 $\pm$ 0.06	<0.05
> 4	32	1.74 $\pm$ 0.12	
Tissue differentiation degree			
Low	11	1.31 $\pm$ 0.09	<0.05
Medium	13	1.59 $\pm$ 0.09	
High	35	1.97 $\pm$ 0.06	
Lymph node metastasis			
Yes	23	1.66 $\pm$ 0.05	>0.05
No	36	1.65 $\pm$ 0.06	
TNM stage			
I	3	0.93 $\pm$ 0.04	<0.05
II	6	1.24 $\pm$ 0.04	
III	50	1.82 $\pm$ 0.06	

Notes: t-test or ANOVA was used according to the number of groups. $p < 0.05$ indicated statistically significant.

To explore the effect of *circ0001313* expression on NSCLC cell proliferation and invasion, we cultured A549 cells and transfected cells with si-NC and si-*circ0001313*. Transfection efficiency was verified using qRT-PCR. si-*circ0001313*-1 and si-*circ0001313*-2 were designed, and one with better effect was selected for subsequent experiments (Figure 1C). Cell transfected with si-*circ0001313* showed remarkably reduced cell proliferation ability (Figure 1D). Transwell assay demonstrated that cell invasion ability following si-*circ0001313* treatment was significantly decreased (Figure 1E). These results indicated that *circ0001313* showed promoting effects on NSCLC cell proliferation and invasion.

miR-452 Competitively Binds to Circ0001313

RNA-FISH detected the location of *circ0001313* in A549 cells and showed that *circ0001313* was mainly located in the cytoplasm (Figure 2A). A binding site between

circ0001313 and *miR-452* was predicted through Starbase (Figure 2B). Dual-luciferase reporter gene assay verified the interaction between *circ0001313* and *miR-452*. *miR-452* overexpression dramatically inhibited the luciferase activity of *circ0001313* wt but had little impact on *circ0001313* mut (Figure 2C). RNA pull-down showed that compared with MUT-*miR-452*, WT-*miR-452* obviously bound to more *circ0001313*, indicating that *miR-452* and *circ0001313* could directly bind to each other (Figure 2D). RIP results showed that compared with IgG, Ago2 remarkably bound more *circ0001313* (Figure 2E), indicating that *circ0001313* could bind directly to Ago2 protein, namely, *miR-452* directly bound to *circ0001313*. And then, we further detected the expression of *miR-452* in tumor and adjacent tissues of 59 patients. The expression of *miR-452* in NSCLC tissues was observed to be significantly lower than that in adjacent tissues (Figure 2F). The correlation between *miR-452* expression and *circ0001313* expression was analyzed and we found a negative correlation (Figure 2G). The above results indicated that *miR-452* competitively bound to *circ0001313*.

Overexpression of miR-452 Inhibits NSCLC Cell Proliferation and Invasion

miR-452 expression in BEAS-2B cells and NSCLC cell lines was detected. The results showed that compared with that in BEAS-2B cells, NSCLC cell lines exhibited decreased *miR-452* expression in different degrees with the lowest expression in A549 cells (Figure 3A). To explore the influence of *miR-452* expression on NSCLC cell growth, we transfected mimic NC, *miR-452* mimic, inhibitor NC and *miR-452* inhibitor, respectively, into A549 cells, and the transfection efficiency was verified using qRT-PCR (Figure 3B). CCK-8 assay indicated that compared with cells in the mimic NC group, cells in the *miR-452* mimic group showed significantly reduced cell proliferation ability; compared with cells in the inhibitor NC group, cells in the *miR-452* inhibitor group exhibited obviously increased cell proliferation ability (Figure 3C). Transwell assay observed that the *miR-452* mimic group showed weakened cell invasion ability relative to the mimic NC group; the *miR-452* inhibitor group exhibited enhanced cell invasion ability compared with the inhibitor NC group (Figure 3D). From all above, *miR-452* played an inhibitory role in NSCLC cell proliferation and invasion.

Figure 1 *Circ0001313* promoted NSCLC cell proliferation and invasion. (A) *circ0001313* expression in NSCLC tissues and its adjacent normal tissues was evaluated by qRT-PCR; (B) *circ0001313* expression in BEAS-2B cells and NSCLC cell lines H1299, A549, NCI-H23 and NCI-H522 was evaluated by qRT-PCR; (C) *circ0001313* expression in cells in the si-NC and si-circ0001313 group was evaluated by qRT-PCR; (D) A549 cell proliferation in response to si-NC and si-circ0001313 examined was by CCK-8 assay; (E) A549 cell invasion ability in response to si-NC and si-circ0001313 tested was by Transwell assay. *vs BEAS-2B cells, $p < 0.05$; #vs the si-NC group, $p < 0.05$. The value in the figure was measurement data, which were expressed as mean $\pm$ standard deviation of three independent experiments. The comparison between two groups was analyzed using t-test. One-way or two-way ANOVA was used for analysis among multiple groups.

miR-452 Targets HMGB3 to Regulate NSCLC Cell Proliferation and Invasion

To explore the downstream regulatory mechanism of *miR-452*, the bioinformatics website Starbase was utilized. *miR-452* was predicted to directly bind to the 3'-UTR sequence of *HMGB3* (Figure 4A). *HMGB3*, a key cell cycle regulator, is implicated in various cancers with its high expression. Dual-luciferase reporter gene assay verified the targeting relationship between *miR-452* and *HMGB3*, and overexpression of *miR-452* significantly repressed the luciferase activity of *HMGB3* wt, but rarely changed the luciferase activity of *HMGB3* mut (Figure 4B). WB detected *HMGB3* protein expression in each group. *HMGB3* protein expression decreased notably after *miR-452* overexpression and increased obviously after *miR-452* silencing (Figure 4C). A549 cells were transfected with mimic NC + overexpressed (oe)-NC, *miR-452* mimic + oe-NC, mimic NC + oe-*HMGB3* and *miR-452* mimic + oe-*HMGB3*. qRT-PCR and WB verified

the expression of *miR-452* and *HMGB3*. Relative to that in the mimic NC + oe-NC group, *miR-452* expression was significantly increased, and *HMGB3* levels were obviously reduced in the *miR-452* mimic + oe-NC group; *miR-452* expression in the mimic NC + oe-*HMGB3* showed no significant difference, while *HMGB3* levels were noticeably increased. Compared with the *miR-452* mimic + oe-NC group, the *miR-452* mimic + oe-*HMGB3* group showed no obvious difference in *miR-452* expression, while exhibited clearly increased *HMGB3* levels (Figure 4D and E). Compared with those in the mimic NC + oe-NC group, cells in the *miR-452* mimic + oe-NC showed remarkably reduced cell proliferation ability, while that of the mimic NC + oe-*HMGB3* group was significantly increased. Cell proliferation in the *miR-452* mimic + oe-*HMGB3* group was clearly increased compared to the *miR-452* mimic + oe-NC group (Figure 4F). Relative to cells in the mimic NC + oe-NC group, cells in the *miR-452* mimic + oe-NC group showed significantly weakened cell

Figure 2 *Circ0001313* interacted with *miR-452* in NSCLC cells. (A) RNA-FISH revealed that *circ0001313* was predominantly distributed in the cytoplasm in A549 cells; (B) the binding sites between *circ0001313* and *miR-452* was predicted by StarBase; (C) the interaction between *circ0001313* and *miR-452* was verified by dual-luciferase reporter gene assay, *vs NC mimic group, $p < 0.05$; (D) the binding between *circ0001313* and *miR-452* was tested by RNA pull-down, *vs the MUT-bio-*miR-452* group, $p < 0.05$; (E). *circ0001313* enrichment pull-downed by IgG or Ago2 antibodies was examined by RIP, *vs IgG, $p < 0.05$; (F) *miR-452* expression in NSCLC tissues and its adjacent normal tissues was evaluated by qRT-PCR; (G), the correlation between *circ0001313* expression and *miR-452* expression in 59 NSCLC patients was analyzed by Pearson's correlation test. The value in the figures was measurement data, which were expressed as mean $\pm$ standard deviation. The comparison between two groups was analyzed using *t*-test. Two-way ANOVA was used for analysis of comparisons among multiple groups. The experiment was repeated three times.

invasion ability, which was notably enhanced in the mimic NC + oe-HMGB3 group. The cell invasion ability of the *miR-452* mimic + oe-HMGB group was obviously increased relative to that of the *miR-452* mimic + oe-NC group (Figure 4G). Moreover, we further examined the expression of *HMGB3* in tumor and adjacent tissues of

59 lung cancer patients. The expression of *HMGB3* in NSCLC tissues was significantly higher than in adjacent tissues (Figure 4H). Furthermore, *HMGB3* was negatively correlated with *miR-452* and positively correlated with *circ0001313* (Figure 4I). Subsequently, we detected the expression of *miR-452* and *HMGB3* in A549 cells with

Figure 3 Overexpression of *miR-452* inhibited NSCLC cell growth. **(A)** *miR-452* expression in BEAS-2B cells and NSCLC cell lines was evaluated by qRT-PCR, *vs BEAS-2B cells, $p < 0.05$; **(B)** *miR-452* expression in cells in each group was evaluated by qRT-PCR; **(C)** cell proliferation in response to *miR-452* mimic or inhibitor was examined by CCK-8 assay; **(D)** cell invasion ability in response to *miR-452* mimic or inhibitor examined by Transwell assay, *vs the mimic NC group, $p < 0.05$; #vs the inhibitor NC group, $p < 0.05$. The value in the figure was measurement data, which were expressed as mean $\pm$ standard deviation. The comparison between two groups was analyzed using t-test. One-way or two-way ANOVA was used for analysis among multiple groups. The experiment was repeated three times.

poor expression of *circ0001313*. The expression of *HMGB3* was significantly decreased after knocking down *circ0001313*, whereas the expression of *miR-452* was significantly increased (Figure 4J). In brief, *miR-452* suppressed NSCLC cell proliferation and invasion via targeting *HMGB3*.

Circ0001313/miR-452/HMGB3/ERK/MAPK Axis Regulates NSCLC Cell Growth

The expression of ERK1/2, p-ERK1/2, p38 MAPK and p-p38 MAPK in the ERK/MAPK pathway was detected after *HMGB3* overexpression. p-ERK1/2 and p-p38 MAPK expression was noticeably higher in cells overexpressing *HMGB3* (Figure 5A). Therefore, we speculated that *HMGB3* might regulate NSCLC cell proliferation and invasion via the ERK/MAPK pathway. Hence, the ERK/MAPK pathway inhibitor PD98059 (50 $\mu\text{mol/L}$, Selleck Chemicals, Houston, TX, USA) was used. p-ERK1/2 and p-p38 MAPK expression of cells treated with the oe-*HMGB3* + PD98059 was obviously reduced relative to that in cells treated with oe-*HMGB3* + DMSO (Figure 5B). Compared with those in the oe-*HMGB3*

+ DMSO group, cells in the oe-*HMGB3* + PD98059 group showed clearly reduced cell proliferation ability (Figure 5C). Cells in the oe-*HMGB3* + PD98059 group exhibited remarkably weakened cell invasion relative to those in the oe-*HMGB3* + DMSO group (Figure 5D). In conclusion, *circ0001313* targeted *miR-452* to upregulate *HMGB3* and activate the ERK/MAPK pathway, thus promoting NSCLC cell growth.

miR-452 Inhibitor Abolishes the Inhibitory Effects of Si-Circ0001313 on Proliferation and Invasion of A549 Cells

To further clarify the regulatory relationship between *miR-452* and *circ0001313*, we transfected *miR-452* inhibitor into A549 cells with poor expression of *circ0001313*, and we detected successful transfection by qRT-PCR (Figure 6A). We then further used WB to detect the expression of *HMGB3* in cells and found that knocking down the expression of *miR-452* resulted in an increase in the protein expression of *HMGB3* in cells (Figure 6B). Subsequently, we assayed cell activity by CCK-8 kits. *miR-452* inhibitor significantly promoted A549 cell activity in the presence of

Figure 4 *miR-452* targeted *HMGB3* expression in NSCLC. (A) binding sites between *miR-452* and *HMGB3* was predicted by StarBase; (B) the targeting relationship between *miR-452* and *HMGB3* was verified by dual-luciferase reporter gene assay, *vs the mimic NC group, $p < 0.05$; (C) *HMGB3* protein levels in response to *miR-452* mimic or inhibitor was analyzed by WB, *vs the mimic NC group, $p < 0.05$; #vs the inhibitor NC group, $p < 0.05$; (D) *miR-452* and *HMGB3* expression after co-transfection was detected using qRT-PCR; (E) *HMGB3* protein expression after co-transfection was analyzed by WB; (F) cell proliferation after co-transfection was examined by CCK-8 assay; (G) cell invasion ability after co-transfection was examined by Transwell assay. *vs the mimic NC + oe-NC group, $p < 0.05$; #vs the *miR-452* mimic + oe-NC group, $p < 0.05$; (H), *HMGB3* expression in NSCLC tissues and its adjacent normal tissues was detected using qRT-PCR; (I), the correlation between *HMGB3* and *circ0001313* expression and between *miR-452* and *HMGB3* expression in 59 NSCLC patients was analyzed by Pearson's correlation test; (J), expression of *miR-452* and *HMGB3* in A549 cells after knockdown of *circ0001313* expression by qRT-PCR, ##vs the si-NC group, $p < 0.01$. The value in the figure was measurement data, which were expressed as mean $\pm$ standard deviation. The comparison between two groups was analyzed using paired t-test. One-way or two-way ANOVA was used for analysis of comparisons among multiple groups. The experiment was repeated three times.

si-circ0001313 (Figure 6C). Moreover, we found by Transwell assays that knocking down *miR-452* significantly restored the number of cells invaded into the Transwell basolateral compartment (Figure 6D).

Discussion

NSCLC represents the most common type of lung cancer and the most frequent cause of mortality in lung cancer patients.⁵ In China, the high incidence of lung cancer is mainly influenced by tobacco consumption and environmental pollution.¹⁸ CircRNAs are members of the

noncoding RNAs, and their diverse functions include adsorbing miRNAs by acting as miRNA sponges, regulating transcription, interacting with RNA-binding proteins, as well as translating pseudogenes.¹⁹ We highlighted that *circ0001313* knockdown regulated the *miR-452/HMGB3* axis and impaired the activation of the ERK/MAPK pathway, thereby inhibiting NSCLC cell proliferation and invasion.

CircRNAs are non-coding RNAs that participate in the regulation of various human cancers, including NSCLC.²⁰ *Circ0001313* is highly expressed in colon cancer tissues

Figure 5 HMGB3 activated the ERK/MAPK pathway. (A), protein expression of ERK1/2, p-ERK1/2, p38 MAPK and p-p38 MAPK in A549 cells was analyzed by WB after overexpression of HMGB3; (B) Protein expression of ERK1/2, p-ERK1/2, p38 MAPK and p-p38 MAPK in A549 cells was analyzed by WB after pathway inhibitor PD98059 or DMSO treatment; (C) cell proliferation after pathway inhibitor PD98059 or DMSO treatment was examined by CCK-8 assay; (D) cell invasion after pathway inhibitor PD98059 or DMSO treatment was examined by Transwell assay. *vs the oe-NC group, $p < 0.05$; #vs the oe-HMGB3 + DMSO, $p < 0.05$. The value in the figure was measurement data, which were expressed as mean $\pm$ standard deviation. The comparison between two groups was analyzed using t-test. Two-way ANOVA was used for analysis of comparisons among multiple groups. The experiment was repeated three times.

and cell lines, and depletion of *circ0001313* repressed cell proliferative ability but induced apoptosis of colon cancer cells.²¹ Similarly, this study observed the aberrant upregulation of *circ0001313* in NSCLC tissues and cell lines. Our data showed that there were significant correlations between *circ0001313* expression and tumor diameter, tissue differentiation degree and TNM stage. Moreover, we revealed that downregulated *circ0001313* suppressed NSCLC cell proliferation and invasion. Similar to our results, *circ0001313* was found to be elevated in NSCLC cells, and *circ0001313* knockdown showed a suppressive effect on NSCLC cell growth.²² It has also been demonstrated that circRNAs possess the ability to bind to miRs via acting as molecular sponges.²³ hsa-circ0001313 is also found to serve a regulatory part in gastric cancer via targeting miR-618.²⁴ Furthermore, a previous study has shown the interactions between another circRNA and miR-452-5p in hepatocellular carcinoma.²⁵ We identified the competitively binding relationship between *circ0001313* and *miR-452*. In addition, *miR-452* was downregulated in NSCLC cells, and overexpression of *miR-452* inhibited NSCLC cell proliferation and invasion. *miR-452* expression, as a significant predictor in NSCLC patients, decreased dramatically in NSCLC.¹⁶ The

relatively low expression of *miR-452* promoted cell invasive ability and strongly related to the advanced tumor stage in NSCLC.²⁶ In addition, the inhibitory role of *miR-452* in proliferation, invasion, and migration of A549 or H460 cells has been previously highlighted.²⁷ Overall, *circ0001313* competitively bound to *miR-452*, thus promoting NSCLC cell proliferation and invasion.

Then, we turned to investigate the downstream mechanism of *miR-452*. Through the screening of bioinformatics website Starbase and the verification of dual-luciferase reporter gene assays, we identified that *miR-452* targeted *HMGB3* to inhibit NSCLC cell growth. Previously, *HMGB3* overexpression is significantly correlated with tumor grade, tumor size, clinical stage, lymph node metastases, and a poor prognosis of NSCLC patients.²⁸ As for its association with miRNAs, *HMGB3* is evidenced to be inversely regulated by miR-452-5p and its knockdown abolished the promotive effects of miR-452-5p inhibitor on growth and metastasis of prostate cancer cells.²⁹ Moreover, *HMGB3* serves a regulatory role in NSCLC with its significantly upregulated expression indicating aggravated lymph node metastases and poor prognosis of NSCLC patients.²⁸ HOXA transcript at the distal tip, a lncRNA, has been reported to positively regulate

Figure 6 miR-452 inhibitor promotes the proliferation and invasion of A549 cells poorly expressing *circ0001313*. (A) the expression of *miR-452* in cells in response to si-circ0001313 + inhibitor NC or si-circ0001313 + *miR-452* inhibitor was detected by qRT-PCR; (B) protein expression of *HMGB3* in A549 cells further transfected with si-circ0001313 + inhibitor NC or si-circ0001313 + *miR-452* inhibitor was examined by WB. (C), cell proliferation in response to si-circ0001313 + inhibitor NC or si-circ0001313 + *miR-452* inhibitor examined by CCK-8 assay; (D) cell invasion ability in response to si-circ0001313 + inhibitor NC or si-circ0001313 + *miR-452* inhibitor was detected using Transwell assay. **vs the si-circ0001313 + inhibitor NC group, $p < 0.01$. The value in the figure was measurement data, which were expressed as mean $\pm$ standard deviation. The comparison between two groups was analyzed using t-test. Two-way ANOVA was used for analysis among multiple groups. The experiment was repeated three times.

HMGB3 expression by acting as a molecular sponge of *miR-615-3p* in NSCLC cells.³⁰ More relevantly, two ceRNA networks involving *circEPSTI1/miR-145/HMGB3* and *circRNA_102179/miR-330-5p/HMGB3* have been documented in NSCLC.^{31,32} Taken together, *circ0001313* promoted NSCLC cell growth via targeting *miR-452* to upregulate *HMGB3*.

Subsequently, we shifted to exploring the downstream possible signaling pathway of *HMGB3*. The ERK/MAPK pathway has been recently evidenced to closely related to NSCLC cell development.^{33,34} Inhibited ERK/MAPK pathway is implicated in suppressed NSCLC cell episodes.³⁵ Moreover, previous studies have verified the relationship between *HMGB3* and the ERK/MAPK pathway. For example, *HMGB3* knockdown remarkably

reduced p-ERK 1/2, and *HMGB3* contributed to glioblastoma multiforme oncogenesis via the MAPK pathway activation.³⁶ We highlighted that upregulated *HMGB3* activated the ERK/MAPK pathway to promote NSCLC cell proliferation and invasion. *HMGB3* induced innate immune responses, including MAPK activation.³⁷ Taken together, *circ0001313* stimulated NSCLC cell growth via the *miR-452/HMGB3* axis and the ERK/MAPK pathway activation.

Conclusion

All in all, this study supported that *circ0001313* competitively bound to *miR-452* to promote *HMGB3* expression, thus activating the ERK/MAPK pathway and promoting NSCLC cell growth (Figure 7). Targeting the *circ0001313*/

Figure 7 Mechanism diagram. *Circ0001313* competitively bound to *miR-452* to promote *HMGB3* expression and thus activate the ERK/MAPK pathway, thereby promoting the proliferation and invasion of NSCLC cells.

miR-452/HMGB3 axis might develop as a new therapeutic approach for NSCLC treatment. Although the current study provides a new perspective for the treatment of NSCLC, the clinical application effect needs to be further verified.

Funding

There is no funding to report.

Disclosure

The authors reported no conflicts of interest in this work.

References

- Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. *Cancer Treat Rev*. 2018;62:39–49. doi:10.1016/j.ctrv.2017.10.002
- Zheng H, Zhan Y, Liu S, et al. The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. *J Exp Clin Cancer Res*. 2018;37(1):226.
- Qiu ZW, Bi JH, Gazdar AF, Song K. Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer. *Genes Chromosomes Cancer*. 2017;56(7):559–569. doi:10.1002/gcc.22460
- Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a Phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. *Ann Oncol*. 2017;28(8):1949–1956. doi:10.1093/annonc/mdx192
- Lobb RJ, van Amerongen R, Wiegman A, Ham S, Larsen JE, Moller A. Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance. *Int J Cancer*. 2017;141(3):614–620. doi:10.1002/ijc.30752
- Du WW, Zhang C, Yang W, Yong T, Awan FM, Yang BB. Identifying and characterizing circRNA-protein interaction. *Theranostics*. 2017;7(17):4183–4191. doi:10.7150/thno.21299
- Yao JT, Zhao SH, Liu QP, et al. Over-expression of CircRNA_100876 in non-small cell lung cancer and its prognostic value. *Pathol Res Pract*. 2017;213(5):453–456. doi:10.1016/j.prp.2017.02.011
- Zhang HD, Jiang LH, Sun DW, Hou JC, Ji ZL. CircRNA: a novel type of biomarker for cancer. *Breast Cancer*. 2018;25(1):1–7. doi:10.1007/s12282-017-0793-9
- Li C, Zhang L, Meng G, et al. Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. *J Cancer Res Clin Oncol*. 2019;145(12):2875–2889. doi:10.1007/s00432-019-03045-4
- Wang L, Peng X, Lu X, Wei Q, Chen M, Liu L. Inhibition of hsa_circ_0001313 (circCCDC66) induction enhances the radio-sensitivity of colon cancer cells via tumor suppressor miR-338-3p: effects of circ_0001313 on colon cancer radio-sensitivity. *Pathol Res Pract*. 2019;215(4):689–696. doi:10.1016/j.prp.2018.12.032
- Hong W, Yu S, Zhuang Y, Zhang Q, Wang J, Gao X. SRCIN1 regulated by circCCDC66/miR-211 is upregulated and promotes cell proliferation in non-small-cell lung cancer. *Biomed Res Int*. 2020;2020:5307641. doi:10.1155/2020/5307641
- Cai X, Lin L, Zhang Q, Wu W, Su A. Bioinformatics analysis of the circRNA-miRNA-mRNA network for non-small cell lung cancer. *J Int Med Res*. 2020;48(6):300060520929167. doi:10.1177/0300060520929167
- Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. *Biomol Concepts*. 2017;8(2):61–81.
- Weidle UH, Birzele F, Nopora A. MicroRNAs as potential targets for therapeutic intervention with metastasis of non-small cell lung cancer. *Cancer Genomics Proteomics*. 2019;16(2):99–119. doi:10.21873/cgp.20116
- Tang T, Zhang GC, Li CF, Liu YF, Wang WY. Decreased miR-452 expression in human colorectal cancer and its tumor suppressive function. *Genet Mol Res*. 2016;15:2. doi:10.4238/gmr.15027730
- He Z, Xia Y, Liu B, et al. Down-regulation of miR-452 is associated with poor prognosis in the non-small-cell lung cancer. *J Thorac Dis*. 2016;8(5):894–900. doi:10.21037/jtd.2016.03.51
- Zhu L, Wang C, Lin S, Zong L. CircKIAA0907 retards cell growth, cell cycle, and autophagy of gastric cancer in vitro and inhibits tumorigenesis in vivo via the miR-452-5p/KAT6B axis. *Med Sci Monit*. 2020;26:e924160. doi:10.12659/MSM.924160
- Hecht SS. Lung carcinogenesis by tobacco smoke. *Int J Cancer*. 2012;131(12):2724–2732. doi:10.1002/ijc.27816
- Wu J, Qi X, Liu L, et al. Emerging epigenetic regulation of circular RNAs in human cancer. *Mol Ther Nucleic Acids*. 2019;16:589–596. doi:10.1016/j.omtn.2019.04.011
- Wang L, Tong X, Zhou Z, et al. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-beta-induced epithelial-mesenchymal transition and metastasis by controlling TIF1gamma in non-small cell lung cancer. *Mol Cancer*. 2018;17(1):140. doi:10.1186/s12943-018-0889-7
- Tu FL, Guo XQ, Wu HX, et al. Circ-0001313/miRNA-510-5p/AKT2 axis promotes the development and progression of colon cancer. *Am J Transl Res*. 2020;12(1):281–291.
- Wang Y, Zhao W, Zhang S. STAT3-induced upregulation of circCCDC66 facilitates the progression of non-small cell lung cancer by targeting miR-33a-5p/KPNA4 axis. *Biomed Pharmacother*. 2020;126:110019. doi:10.1016/j.biopha.2020.110019
- Filippenkov IB, Kalinichenko EO, Limborska SA, Dergunova LV. Circular RNAs-one of the enigmas of the brain. *Neurogenetics*. 2017;18(1):1–6. doi:10.1007/s10048-016-0490-4
- Zhang Q, Miao Y, Fu Q, et al. CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618/BCL2 axis. *Biochem Biophys Res Commun*. 2020;526(3):713–720.

25. Yang W, Ju HY, Tian XF. Circular RNA-ABCB10 suppresses hepatocellular carcinoma progression through upregulating NRPI/ABL2 via sponging miR-340-5p/miR-452-5p. *Eur Rev Med Pharmacol Sci.* 2020;24(5):2347–2357.
26. He Z, Xia Y, Pan C, et al. Up-regulation of MiR-452 inhibits metastasis of non-small cell lung cancer by regulating BMI1. *Cell Physiol Biochem.* 2015;37(1):387–398. doi:10.1159/000430362
27. Zhang Y, Han L, Pang J, Wang Y, Feng F, Jiang Q. Expression of microRNA-452 via adenoviral vector inhibits non-small cell lung cancer cells proliferation and metastasis. *Tumour Biol.* 2016;37(6):8259–8270. doi:10.1007/s13277-015-4725-z
28. Song N, Liu B, Wu JL, et al. Prognostic value of HMGB3 expression in patients with non-small cell lung cancer. *Tumour Biol.* 2013;34(5):2599–2603. doi:10.1007/s13277-013-0807-y
29. Song X, Wang H, Wu J, Sun Y. Long noncoding RNA SOX2-OT knockdown inhibits proliferation and metastasis of prostate cancer cells through modulating miR-452-5p/HMGB3 axis and inactivating wnt/beta-catenin pathway. *Cancer Biother Radiopharm.* 2020. doi:10.1089/cbr.2019.3479
30. Shi J, Wang H, Feng W, et al. Long non-coding RNA HOTTIP promotes hypoxia-induced glycolysis through targeting miR-615-3p/HMGB3 axis in non-small cell lung cancer cells. *Eur J Pharmacol.* 2019;862:172615. doi:10.1016/j.ejphar.2019.172615
31. Xie Y, Wang L, Yang D. CircEPSTI1 promotes the progression of non-small cell lung cancer through miR-145/HMGB3 axis. *Cancer Manag Res.* 2020;12:6827–6836. doi:10.2147/CMAR.S252893
32. Zhou ZF, Wei Z, Yao JC, et al. CircRNA_102179 promotes the proliferation, migration and invasion in non-small cell lung cancer cells by regulating miR-330-5p/HMGB3 axis. *Pathol Res Pract.* 2020;216(11):153144. doi:10.1016/j.prp.2020.153144
33. Liu C, Li H, Jia J, Ruan X, Liu Y, Zhang X. High metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) expression promotes proliferation, migration, and invasion of non-small cell lung cancer via ERK/Mitogen-activated protein kinase (MAPK) signaling pathway. *Med Sci Monit.* 2019;25:5143–5149. doi:10.12659/MSM.913308
34. He C, Bai X, Li Y, et al. Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5. *Cell Cycle.* 2019;18(23):3404–3419. doi:10.1080/15384101.2019.1678966
35. Cao Q, Mao ZD, Shi YJ, et al. MicroRNA-7 inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells by targeting FAK through ERK/MAPK signaling pathway. *Oncotarget.* 2016;7(47):77468–77481. doi:10.18632/oncotarget.12684
36. Liu J, Wang L, Li X. HMGB3 promotes the proliferation and metastasis of glioblastoma and is negatively regulated by miR-200b-3p and miR-200c-3p. *Cell Biochem Funct.* 2018;36(7):357–365. doi:10.1002/cbf.3355
37. Choi HW, Manohar M, Manosalva P, Tian M, Moreau M, Klessig DF. Activation of plant innate immunity by extracellular high mobility group box 3 and its inhibition by salicylic acid. *PLoS Pathog.* 2016;12(3):e1005518. doi:10.1371/journal.ppat.1005518

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>